Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670382 · ClinicalTrials.gov registry record · NA
Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids
A NA study of Metabolic Syndrome, sponsored by Tufts University.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02670382: Completed NA study of Metabolic Syndrome, sponsored by Tufts University.
NCT02670382 is a NA study of Metabolic Syndrome that has completed, run by Tufts University. The registered enrollment target is 24 participants, below the 1,205-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02670382, a NA study of Metabolic Syndrome, has completed, sponsored by Tufts University.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to provide critical information regarding both common and distinctive roles of EPA and DHA in systemic inflammation and lipid metabolism.
Primary Outcome
plasma levels in pg/mL
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT DHA
- DIETARY_SUPPLEMENT EPA
- DIETARY_SUPPLEMENT sunflower oil
Study Locations (1)
Massachusetts
- Jean Mayer Human Nutrition Research Center on Aging at Tufts University - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-03 |
| Est. Completion | 2020-10 |
| Phase | NA |
What the finished NCT02670382 record still lists
NCT02670382 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,205-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Metabolic Syndrome appearing as the primary indexed condition, and to 3 interventions - of which DHA is the first listed.
NCT02670382 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02670382 about?
NCT02670382 is a clinical study titled "Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids". The objective of this study is to provide critical information regarding both common and distinctive roles of EPA and DHA in systemic inflammation and lipid metabolism.
What is the current status of trial NCT02670382?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2016-03. Estimated completion is 2020-10.
What conditions does trial NCT02670382 study?
This clinical trial studies the following conditions: Metabolic Syndrome.
What interventions are being tested in trial NCT02670382?
The interventions under investigation include: DHA (DIETARY_SUPPLEMENT), EPA (DIETARY_SUPPLEMENT), sunflower oil (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02670382?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02670382 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02670382's enrollment target sits among peer trials
24 86th of 102 higher than 16 of 102 other Metabolic Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metabolic Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Animal and Plant Proteins and Glucose Metabolism
RECRUITING · NA
-
VR Stimulation of Exercise Response in Sedentary Humans
RECRUITING · NA
-
Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Testing the Adipose Expandability Hypothesis in Vivo During Overfeeding
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia